1.85

4.64% -0.09

Pre-market: 1.85

eFFECTOR Therapeutics Inc (EFTR)

Overview News Price History Option Chain Discussions Forecast

eFFECTOR Therapeutics Inc stock is currently priced at $1.85, with a 24-hour trading volume of 107.92K. It has seen a -4.64% decreased in the last 24 hours and a -85.00% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.91 pivot point. If it approaches the $1.81 support level, significant changes may occur.

Previous Close:

$1.94

Open:

$1.9

24h Volume:

107.92K

Market Cap:

$6.82M

Revenue:

Net Income/Loss:

$-35.94M

P/E Ratio:

-2.1512

EPS:

-0.86

Net Cash Flow:

$-30.82M

1W Performance:

-2.12%

1M Performance:

-85.00%

6M Performance:

+224.56%

1Y Performance:

+369.19%

1D Range:

$1.80

$1.94

52W Range:

$0.345

$17.75

eFFECTOR Therapeutics Inc Stock (EFTR) Company Profile

Name

eFFECTOR Therapeutics Inc

Sector

Healthcare (1198)

Industry

Biotechnology (688)

Phone

858 925 8215

Address

142 North Cedros Avenue, Suite B, Solana Beach

Employee

Twitter

Next Earnings Date

2024-05-07

Latest SEC Filings

EFTR's Discussions on Twitter

eFFECTOR Therapeutics Inc Stock (EFTR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-25-22	Downgrade	Stifel	Buy → Hold
Nov-09-21	Upgrade	Stifel	Hold → Buy
Oct-12-21	Initiated	Credit Suisse	Outperform
Oct-04-21	Initiated	Mizuho	Buy
Sep-21-21	Initiated	JMP Securities	Mkt Outperform
Sep-20-21	Initiated	Stifel	Hold
Sep-13-21	Initiated	Cantor Fitzgerald	Overweight

View All

eFFECTOR Therapeutics Inc Stock (EFTR) Latest News

Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings

Benzinga

Dow Jumps Over 100 Points; US Jobless Claims Increase To 221,000

Benzinga

eFFECTOR Therapeutics Inc Stock (EFTR) Financials Data

eFFECTOR Therapeutics Inc (EFTR) Net Income 2024

EFTR net income (TTM) was -$35.94 million for the quarter ending September 30, 2023, a -736.80% decrease year-over-year.

eFFECTOR Therapeutics Inc (EFTR) Cash Flow 2024

EFTR recorded a free cash flow (TTM) of -$30.82 million for the quarter ending September 30, 2023, a -26.61% decrease year-over-year.

eFFECTOR Therapeutics Inc (EFTR) Earnings per Share 2024

EFTR earnings per share (TTM) was -$19.00 for the quarter ending September 30, 2023, a -790.91% decline year-over-year.

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.